Product Document Searching Made Easy by 2D Code! | TCI Chemistry News October 2025 | [TCIPracticalExample] Di-Cbz Guanidinylation of Amine... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 162011-90-7 | 產品號碼: R0206
| 產品號碼 | R0206 |
純度/分析方法 
|
>98.0%(GC) |
| 分子式 / 分子量 | C__1__7H__1__4O__4S = 314.36 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| 包裝和容器
|
250MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 162011-90-7 |
| Reaxys-RN | 8269007 |
| PubChem Substance ID | 354335586 |
| Merck Index(14) | 8248 |
| MDL編號 | MFCD00935806 |
產品規格
| Appearance | White to Yellow to Orange powder to crystal |
| Purity(GC) | min. 98.0 % |
| Melting point | 207.0 to 211.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 209 °C |
| 水溶性 | Insoluble |
| Degree of solubility in water | 472 mg/l 25 °C |
| 溶解性（微溶於） | Methanol |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
| RTECS # | LU5135000 |
運輸資料
| HS編碼* | 2932.20-000 |
Application
Rofecoxib: A Selective Cyclooxygenase-2 (COX-2) Inhibitor
Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID), and a selective cyclooxygenase-2 (COX-2) inhibitor. The mechanism of action is mainly by inhibition of the enzyme COX in the arachidonic acid metabolism pathway, resulting in reduced prostaglandin synthesis. In theory, a drug that selectively inhibited COX-2 might block inflammation, pain, and fever produced by prostaglandins while reducing the side effects (gastric erosions and ulcers) associated with inhibition of COX-1. For your reference, rofecoxib was withdrawn from the medicine market in 2004 after it was shown that long-term clinical use could increase the risk of heart attack and stroke. (The product is for research purpose only.)
References
- The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
- Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
- Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
- Progress in COX-2 inhibitors: a journey so far (a review)
- Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection
- Review of the applications of different analytical techniques for coxibs research (a review)
PubMed Literature
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。